Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (NYSE: BDX) has announced a $35 million investment to expand its prefilled flush syringe manufacturing capacity at its Columbus, Nebraska facility. The expansion will create approximately 50 new jobs and increase production of BD® PosiFlush™ Prefilled Flush Syringes by hundreds of millions of units annually.
The company has already invested over $80 million in the past three years, increasing U.S. production by more than 750 million units, including a 10% increase this year. This investment is part of BD's larger $2.5 billion commitment to enhance U.S. manufacturing capacity over the next five years.
The Columbus facility, operating for over 75 years, is the largest manufacturer of prefilled flush devices in the U.S. BD currently operates more than 30 U.S. manufacturing and distribution facilities across 17 states and Puerto Rico, employing over 10,000 people.
BD (NYSE: BDX) has submitted an FDA application for a groundbreaking at-home HPV testing solution that could revolutionize cervical cancer screening. The innovative system combines a user-friendly self-collection swab with advanced laboratory robotics through the BD COR™ System.
The technology detects more high-risk HPV strains than any other available test and features a convenient self-collection process that eliminates the need for in-office gynecological visits. According to a Harris Poll survey, 72% of U.S. women have delayed gynecology visits, while 81% desire more comfortable testing options. The BD Onclarity™ Assay has been included in ASCCP's Enduring Risk-Based Management Guidelines, and self-collection testing is currently under consideration in USPSTF draft recommendations.
BD (NYSE:BDX) has received FDA 510(k) clearance for its BD Veritor™ System for SARS-CoV-2, a rapid COVID-19 antigen test. The digital test delivers results in approximately 15 minutes at various point-of-care locations including doctors' offices, urgent care centers, and retail clinics.
The test, previously available under Emergency Use Authorization since September 2020, will transition to the new FDA-cleared version in early fall 2025. The BD Veritor™ System uses chromatographic digital lateral flow immunoassay technology to provide objective results from nasal swab specimens taken within six days of symptom onset, and is designed for use in CLIA-waived environments.
BD (NYSE: BDX) has announced its first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The announcement follows successful outcomes from over 50 pre-clinical and clinical studies, with 100% of participants indicating likely future use of the device.
The BD Libertas™ Wearable Injector is designed to enable home-based self-injection of biologics, potentially converting treatments from hospital-based infusions to at-home care. The device supports delivery of high-viscosity biologics up to 50 centipoise and is available in 2-5mL and 5-10mL configurations. This development comes as the biologics market is projected to reach $670 billion by 2030.
BD (NYSE: BDX), a leading global medical technology company, has announced its quarterly dividend declaration. The Board of Directors has declared a quarterly dividend of $1.04 per common share. The dividend will be paid on September 30, 2025, to shareholders of record as of September 8, 2025. Based on this quarterly payout, the indicated annual dividend rate stands at $4.16 per share.
Waters (NYSE:WAT) and BD have announced a transformative $17.5 billion merger combining BD's Biosciences & Diagnostic Solutions business with Waters through a tax-efficient Reverse Morris Trust transaction. The deal will create a leading life science and diagnostics company with expected 2025 pro forma sales of $6.5 billion and adjusted EBITDA of $2.0 billion.
The merger doubles Waters' total addressable market to $40 billion and increases annual recurring revenue to over 70%. The combined entity expects $345 million in annualized EBITDA synergies by 2030, including $200 million in cost synergies by year three and $290 million in revenue synergies by year five. The transaction is expected to be accretive to adjusted EPS in the first year.
Post-merger, Waters' CEO Udit Batra will lead the combined company, which will maintain the Waters name and NYSE:WAT listing. BD shareholders will own 39.2% of the combined company, while Waters shareholders will retain 60.8%. The deal is expected to close around Q1 2026.
BD (NYSE: BDX) has appointed Bilal Muhsin as Executive Vice President and future President of its Connected Care segment, effective July 2, 2025. Muhsin, who will report to CEO Tom Polen, joins from Masimo where he served as COO during his 25-year tenure.
In this newly created role, Muhsin will lead BD's Connected Care strategy, focusing on advanced analytics and AI solutions alongside smart devices to enhance patient care efficiency. The appointment aligns with BD's transformation into a pure-play MedTech leader, emphasizing connected medication management, advanced workflow robotics, and smart monitoring solutions.
Muhsin brings significant expertise in medical engineering and software development, holding over 50 patents in Medical Systems Communication, Analytics, and Patient Monitoring Systems.
BD (NYSE: BDX) has announced the initiation of XTRACT, a patient data registry to evaluate real-world outcomes of its Rotarex™ Atherectomy System in treating peripheral artery disease (PAD). The registry will enroll up to 600 patients across approximately 100 clinical sites in the United States, with patient follow-ups at 30 days, 6 months, and 12 months post-procedure.
The Rotarex™ System is a minimally invasive device designed to remove both plaque and thrombus in peripheral arteries, serving as both an atherectomy and thrombectomy device. The study, led by Dr. Prakash Krishnan and Dr. Todd Berland, aims to assess the system's clinical performance in treating PAD, a condition affecting over 21 million Americans and 200 million people worldwide.
BD (NYSE: BDX), a leading global medical technology company, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025, at 2:00 pm Eastern Time. Investors and interested parties can access the live webcast through BD's investor relations website at investors.bd.com. A replay of the presentation will be made available on the same platform after the event concludes.